Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Acquiring Company
Ambrose Healthcare
Acquired Company
AM-Pharma
United Kingdom
UtrechtBiotechnologyHealth CareTherapeuticsPharmaceuticalBiotechnologyPharmaceuticalDescription
Ambrose Healthcare has acquired 100% of the shares of Dutch pharma company AM-Pharma. The deal gives Ambrose rights to ilofotase alfa, an investigational enzyme replacement therapy for hypophosphatasia, and an established base in Utrecht, Netherlands. AM-Pharma shareholders may receive up to €161m in upfront and milestone payments, plus royalties on future sales.
Fundz sees it the moment Ambrose Healthcare makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired AM-Pharma?
AM-Pharma was acquired by Ambrose Healthcare, based in United Kingdom. The deal was reported on October 20, 2026. Ambrose Healthcare is a British pharmaceutical company developing rare disease therapies. Ambrose Healthcare is privately held and operates in Biotechnology.
When did Ambrose Healthcare acquire AM-Pharma?
Ambrose Healthcare's acquisition of AM-Pharma was reported on October 20, 2026. Ambrose Healthcare has acquired 100% of the shares of Dutch pharma company AM-Pharma. The deal gives Ambrose rights to ilofotase alfa, an investigational enzyme replacement therapy for hypophosphatasia, and an established base in Utrecht, Netherlands. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does AM-Pharma do?
AM-Pharma is a Dutch pharmaceutical company developing enzyme replacement therapies for rare diseases. Its lead investigational asset is ilofotase alfa for hypophosphatasia, which is in Phase II-ready development. It is privately held, operating in Biotechnology, and is based in Utrecht.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.